Eledon Pharmaceuticals, Inc. — Director's Dealing 2017

Nov 6, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Novus Therapeutics, Inc. (NVUS)
CIK: 0001404281
Period of Report: 2017-11-06

Reporting Person: TURKEL CATHERINE C. (President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-11-06	Stock Option (Right to Buy)	$4.21	A	50000	Acquired	2027-11-06	Common Stock (50000)	Direct

Footnotes

F1: This option represents a right to purchase a total of 50,000 shares of the Issuer's Common Stock one quarter of which will become fully vested and exercisable on 11/6/2018, with the remaining 37,500 shares vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer through each vesting date.